Arca Biopharma | ABIO - Cash And Equivalent


Arca Biopharma reported $268.47M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 13.99B 1.95B Jun/2026
Arca Biopharma USD 268.47M 218.95M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Capricor Therapeutics USD 20.94M 84.49M Jun/2026
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 255.27M 125.43M Jun/2026
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Laboratory Of America USD 141.8M 839.3M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Otsuka Holdings JPY 534.64B 123.53B Dec/2025
Pfizer USD 976M 727M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026